Whitehawk Therapeutics

TAMPA – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) is planning preclinical studies that pair its PH1 spliceosome-modulating payload with Whitehawk Therapeutics' topoisomerase I inhibitor (TOP1i) ADC platform, CEO Abizer Gaslightwala said in a Virtual Investor "What This Means" interview.

Whitehawk studies target dual-payload synergy

The preclinical work is designed to assess synergy between the two payload classes and to generate data that could support future development of next-generation ADCs. The announcement does not disclose financial terms for the collaboration.

Gaslightwala said recent strategic transactions show the market placing growing value on novel payload innovation. Akari argues PH1 extends beyond conventional payload approaches, and management believes the Whitehawk tie-up supports the platform's broad applicability across future oncology programs.

TAMPA, FL – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) is pairing its proprietary PH1 spliceosome-modulating payload with WhiteHawk Therapeutics' TOP1 inhibitor antibody drug conjugate (ADC) platform to test a dual-payload approach in oncology. President and CEO Abizer Gaslightwala laid out the rationale in a new CEO Corner segment released today. The release does not disclose financial terms.

Akari combines two payload mechanisms in one research program

The strategic research collaboration joins PH1, which targets RNA splicing, with WhiteHawk's TOP1 inhibitor technology. Gaslightwala said the ADC field is moving beyond single-payload development toward combinations of complementary mechanisms. Akari expects the pairing to broaden therapeutic activity and to demonstrate the applicability of PH1 across multiple uses.

Tampa – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) reported a second-quarter 2026 net loss of $4.8 million, up from $1.9 million a year earlier, as research and development spending tripled to $2.1 million ahead of a planned Phase 1 start for its lead antibody drug conjugate (ADC), AKTX-101, in mid-2027.

Akari raised $8.6 million gross in the quarter, lifting cash to $7.7 million

The company closed a private placement with $5.5 million in gross proceeds and booked $3.1 million in gross proceeds from warrant exercises. Total gross financing was approximately $8.6 million, with approximately $8.0 million in net proceeds. Cash stood at $7.7 million on June 30, 2026, up from $5.2 million at December 31, 2025. Akari said long-term strategic investors led the financing.

Pleasanton, Calif. – October 07, 2026 -- More than 175 emerging biotechs have adopted Veeva Basics, a suite of pre-configured, pre-validated applications spanning clinical, regulatory, quality, medical, and commercial functions, Veeva Systems (NYSE: VEEV) announced.

Biotechs deploy Veeva Basics applications in weeks instead of months

The pre-configured systems allow high-growth companies to move from startup to commercialization without building internal IT infrastructure or managing complex customizations. Whitehawk Therapeutics, a company with under 40 employees developing antibody-drug conjugates for difficult-to-treat cancers, used the platform to replace paper-based processes. "Veeva Basics redefined how we operate, significantly improving processes across regulatory and quality for greater speed and compliance," said Bryan Ball, chief technology operations officer at Whitehawk Therapeutics.

Morristown, N.J. – September 17, 2026 -- Whitehawk Therapeutics (Nasdaq: WHWK) presented real-world data at the IASLC 2026 World Conference on Lung Cancer in Seoul showing that PTK7 expression remains stable in pretreated, EGFR wild-type non-small cell lung cancer (NSCLC), reinforcing the target biology behind its Phase 1 antibody-drug conjugate (ADC) HWK-007.